NCT06002529

Hemodiafiltration With Endogenous Reinfusion on Uremic Toxins Clearance of Maintenance Hemodialysis Patients

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

1.1Primary Objective To evaluate the clearance rate of uremic toxin β2-microglobulin (β2-MG), indoxyl sulfate and λ-free light chain (λFLC) by HFR. 1.2Secondary Objectives 1.1.1 To evaluate the clearance of low molecular weight uremic toxin urea (spKt/V, URR). 1.1.2 To evaluate the clearance of other middle molecules and macromolecular uremic toxins, including α1-microglobulin (α1-MG), κ-free light chain (κFLC), homocysteine (Hcy), interleukin-6 (IL-6), p-cresol, YKL-40, complement factor D (CFD), leptin, hippuric acid, trimethylamine oxide (TMAO), asymmetric dimethylarginine (ADMA), tumor necrosis factor-α (TNF- α), myoglobin, fibroblast growth factor 23 (FGF23) and intact parathyroid hormone (iPTH). 1.1.3 To evaluate the clearance of serum albumin, branched chain amino acids and vitamins A, C, E. 1.1.4 To evaluate the comfort of HFR treatment for MHD patients.

Conditions

• To Evaluate the Clearance Rate of Uremic Toxin by HFR

Interventions

Type	Name	Description
OTHER	HFR	patient received HFR treatment

Timeline

• Start date: 2023-08-18
• Primary completion: 2025-07-01
• Completion: 2025-07-01
• First posted: 2023-08-21
• Last updated: 2023-08-21